Advanced

A selective tumor microvasculature thrombogen that targets a novel receptor complex in the tumor angiogenic microenvironment

El-Sheikh, A; Borgstrom, P; Bhattacharjee, G; Belting, Mattias LU and Edgington, T S (2005) In Cancer Research 65(23). p.11109-11117
Abstract
We have previously shown that part of the heparin-binding domain of the vascular endothelial growth factor (VEGF), designated HBDt, localizes very selectively to surfaces of the endothelial cells of U blood vessels. Here, we have coupled the HBDt to the extracellular domain of tissue factor (TFt), to locally initiate the thrombogenic cascade. In tumor-bearing mice, infusion of this HBDt.TFt results in rapid occlusive thrombosis selective only for tumor microvasculature with resultant infarctive destruction of tumors. We now show that infusion of an optimal combination of this HBDt.TFt and its requisite cofactor (factor VIIa) in tumor models results in significant tumor eradication. Binding studies and confocal microscopy indicate that the... (More)
We have previously shown that part of the heparin-binding domain of the vascular endothelial growth factor (VEGF), designated HBDt, localizes very selectively to surfaces of the endothelial cells of U blood vessels. Here, we have coupled the HBDt to the extracellular domain of tissue factor (TFt), to locally initiate the thrombogenic cascade. In tumor-bearing mice, infusion of this HBDt.TFt results in rapid occlusive thrombosis selective only for tumor microvasculature with resultant infarctive destruction of tumors. We now show that infusion of an optimal combination of this HBDt.TFt and its requisite cofactor (factor VIIa) in tumor models results in significant tumor eradication. Binding studies and confocal microscopy indicate that the target for the HBDt.TFt seems to be a trimolecular complex of chondroitin C sulfate proteoglycan, neuropilin-1, and VEGF receptor-2, overexpressed together only in highly angiogenic sites of the tumor microenvironment. The HBDt.TFt was also colocalized with the trimolecular receptor complex in endothelial sprouts from tumor tissues, and its binding inhibited the growth of such sprouts. In vitro, we show that the HBDt structure has its highest affinity for chondroitin 6 sulfate. We show the potential of this HBDt.TFt as a candidate therapeutic and elucidate its target in vivo. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Cancer Research
volume
65
issue
23
pages
11109 - 11117
publisher
American Association for Cancer Research Inc.
external identifiers
  • wos:000233508200059
  • scopus:28244486499
ISSN
1538-7445
DOI
10.1158/0008-5472.CAN-05-2733
language
English
LU publication?
yes
id
d12d6a64-be8d-45e1-8a9b-622cf7284290 (old id 212321)
date added to LUP
2007-08-02 15:51:52
date last changed
2017-01-01 06:40:08
@article{d12d6a64-be8d-45e1-8a9b-622cf7284290,
  abstract     = {We have previously shown that part of the heparin-binding domain of the vascular endothelial growth factor (VEGF), designated HBDt, localizes very selectively to surfaces of the endothelial cells of U blood vessels. Here, we have coupled the HBDt to the extracellular domain of tissue factor (TFt), to locally initiate the thrombogenic cascade. In tumor-bearing mice, infusion of this HBDt.TFt results in rapid occlusive thrombosis selective only for tumor microvasculature with resultant infarctive destruction of tumors. We now show that infusion of an optimal combination of this HBDt.TFt and its requisite cofactor (factor VIIa) in tumor models results in significant tumor eradication. Binding studies and confocal microscopy indicate that the target for the HBDt.TFt seems to be a trimolecular complex of chondroitin C sulfate proteoglycan, neuropilin-1, and VEGF receptor-2, overexpressed together only in highly angiogenic sites of the tumor microenvironment. The HBDt.TFt was also colocalized with the trimolecular receptor complex in endothelial sprouts from tumor tissues, and its binding inhibited the growth of such sprouts. In vitro, we show that the HBDt structure has its highest affinity for chondroitin 6 sulfate. We show the potential of this HBDt.TFt as a candidate therapeutic and elucidate its target in vivo.},
  author       = {El-Sheikh, A and Borgstrom, P and Bhattacharjee, G and Belting, Mattias and Edgington, T S},
  issn         = {1538-7445},
  language     = {eng},
  number       = {23},
  pages        = {11109--11117},
  publisher    = {American Association for Cancer Research Inc.},
  series       = {Cancer Research},
  title        = {A selective tumor microvasculature thrombogen that targets a novel receptor complex in the tumor angiogenic microenvironment},
  url          = {http://dx.doi.org/10.1158/0008-5472.CAN-05-2733},
  volume       = {65},
  year         = {2005},
}